证券记录 · 已归档季度
RVTY
Revvity, Inc. · Healthcare · Medical - Diagnostics & Research
16被追踪持有人
+1Δ持有人
42.02M持有股份
$4.06B报告持仓市值
+3新建仓位
−2清仓
动量输入(同类管理人):
持有人广度 +6.7% ·
股份流向 -3.7% ·
净新建仓位 +6.2%
· 公式
持有人分散化:持有人数增多,合计持仓比例缩小。
所有持股数据:仅限已追踪的 13F 管理人,普通股持仓,报告期 Q2 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 131 | +9 | 65.85M | $7.33B | +14 | −6 |
| Q1 2026 | 126 | -7 | 72.99M | $6.39B | +4 | −12 |
| Q4 2025 | 133 | 0 | 75.39M | $7.30B | +3 | −2 |
| Q3 2025 | 19 | +1 | 44.69M | $3.92B | +1 | −1 |
| Q2 2025 | 16 | +1 | 42.02M | $4.06B | +3 | −2 |
| Q1 2025 | 12 | -1 | 20.50M | $2.17B | n/a | −1 |
| Q4 2024 | 13 | 0 | 18.11M | $2.02B | +1 | −1 |
| Q3 2024 | 12 | -1 | 11.86M | $1.51B | +1 | −2 |
| Q2 2024 | 13 | n/a | 11.86M | $1.24B | n/a | n/a |
持有人 · Q2 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (被动) | 14.09M | n/a | $1.36B | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (被动) | 8.86M | n/a | $856.49M | 0.0% | n/c | 1 | SEC ↗ ×20 |
| 3 | T. Rowe Price ✦ | 7.98M | -16.6% | $771.64M | 0.1% | ▼ Trim | 5 | SEC ↗ ×2 |
| 4 | State Street Global Advisors ✦ (被动) | 5.02M | -2.9% | $485.29M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (被动) | 2.98M | -0.6% | $286.51M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 6 | PRIMECAP Management ✦ | 1.36M | +18.7% | $131.50M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 7 | Norges Bank ✦ (被动) | 1.29M | +3.7% | $124.57M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 8 | Fidelity (FMR) ✦ | 209.43K | n/a | $20.26M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 9 | Gotham Asset Management ✦ | 100.06K | -7.7% | $9.68M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 10 | Arrowstreet Capital ✦ | 48.29K | 新增 | $4.67M | 0.0% | New | 1 | SEC ↗ |
| 11 | Millennium Management ✦ | 28.89K | -58.4% | $2.79M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 12 | Wellington Management ✦ | 23.20K | +2.9% | $2.24M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 13 | AQR Capital Management ✦ | 16.67K | +97.3% | $1.61M | 0.0% | ▲ Add | 5 | SEC ↗ ×4 |
| 14 | Fisher Asset Management ✦ | 15.56K | -74.9% | $1.51M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 12.88K | 新增 | $1.25M | 0.0% | New | 1 | SEC ↗ ×2 |
| 16 | Two Sigma Investments ✦ | 2.60K | 新增 | $251,762 | 0.0% | New | 1 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例,即持仓信心指标。✦ = 精选管理人。
新增买入方
| Arrowstreet Capital | $4.67M | 0.0% |
| Citadel Advisors | $1.25M | 0.0% |
| Two Sigma Investments | $251,762 | 0.0% |
已清仓
| Adage Capital Partners | $11.75M | 曾为 0.0% |
| Marshall Wace | $308,936 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构(SEC结构化数据, Q1 2026): 495 持有人, 115.11M 股份, $7.19B 已申报. 这是与上方被追踪全域数据不同的较早期间,两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券:基于共同持有计数,而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Sep 21
Krakowiak Maxwell
Officer · 1.63K 股 · $235,728
Sep 16
Vohra Tajinder S
Officer · 7.33K 股 · $1.03M
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
Oct 07
SC 13G/A: PRICE T ROWE ASSOCIATES INC /MD/
Sep 08
SC 13G/A: T. Rowe Price Investment Management…
Aug 14
SC 13G/A: T. Rowe Price Investment Management…
Aug 14
SC 13G/A: PRICE T ROWE ASSOCIATES INC /MD/
数据来源: 持股数据来源于已解析的13F普通股持仓(被追踪范围,变动对比集);内部人行为来自Form 3/4/5;重大持股来自Schedule 13D/13G;所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2025 ·
方法论 ·
通过API获取此数据